JP Morgan Chase’s Mersana Therapeutics MRSN Stock Holding History

JP Morgan Chase’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,000	Closed	-$1.11M	–	7589
2024 Q4	$1.11M	Buy	+31,000	New	+$1.6M	﹤0.01%	4560
2023 Q3	–	Sell	-3,044	Closed	-$250K	–	7629
2023 Q2	$250K	Buy	+3,044	New	+$445K	﹤0.01%	4948
2021 Q3	–	Sell	-2,316	Closed	-$786K	–	6673
2021 Q2	$786K	Hold	2,316	–	–	﹤0.01%	4434
2021 Q1	$937K	Buy	+2,316	New	+$1.12M	﹤0.01%	4279

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's MRSN Position: Q1 2026 in Review

JP Morgan Chase sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 112 shares — an estimated $3.24K sold.

JP Morgan Chase first reported a position in MRSN in Q2 2017 and held it in 35 quarters. The position peaked at $6.39M in Q1 2024. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

JP Morgan Chase reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
JP Morgan Chase sold 112 Mersana Therapeutics shares in Q1 2026, an estimated $3.24K.
JP Morgan Chase first reported a position in Mersana Therapeutics in Q2 2017 and held it in 35 quarters.
JP Morgan Chase's Mersana Therapeutics position peaked at $6.39M in Q1 2024.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.